Revisiting salt and water retention: New diuretics, aquaretics, and natriuretics

Medical Clinics of North America

Volumn 87, Issue 2, 2003, Pages 475-491

  Costello Boerrigter, Lisa C ^a   Boerrigter, Guido ^a   Burnett Jr , John C ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE A1 RECEPTOR ANTAGONIST; ALDOSTERONE; ALDOSTERONE ANTAGONIST; ARGIPRESSIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CHLORTALIDONE; CONIVAPTAN; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FUROSEMIDE; HYDROCHLOROTHIAZIDE; LOOP DIURETIC AGENT; NATRIURETIC FACTOR; NAXIFYLLINE; POTASSIUM SPARING DIURETIC AGENT; SPIRONOLACTONE; THIAZIDE DIURETIC AGENT; TOLVAPTAN; TRANSFORMING GROWTH FACTOR; TRIAMTERENE; UNINDEXED DRUG; VASOPRESSIN; VASOPRESSIN RECEPTOR; VASOPRESSIN RECEPTOR ANTAGONIST; VASOPRESSIN V1 RECEPTOR; VASOPRESSIN V2 RECEPTOR; XANTHINE DERIVATIVE; XIPAMIDE;

ADRENERGIC SYSTEM; APOPTOSIS; AQUARESIS; ARTICLE; CELL DEATH; CONGESTIVE HEART FAILURE; COST BENEFIT ANALYSIS; DIABETES MELLITUS; DISEASE COURSE; DIURESIS; GLOMERULUS FILTRATION RATE; GYNECOMASTIA; HEART ARRHYTHMIA; HEART MUSCLE FIBROSIS; HEART MUSCLE NECROSIS; HORMONAL REGULATION; HUMAN; HYPERLIPIDEMIA; HYPOKALEMIA; HYPONATREMIA; IMPOTENCE; KIDNEY DYSFUNCTION; LONG TERM CARE; MENSTRUAL IRREGULARITY; MORBIDITY; MORTALITY; MUSCLE CELL; NATRIURESIS; OTOTOXICITY; POTASSIUM TRANSPORT; PRIORITY JOURNAL; REGULATORY MECHANISM; SODIUM RETENTION; THIRST; WATER RETENTION;

EID: 0037349182     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0025-7125(02)00181-5     Document Type: Article

References (62)

1. Poole-Wilson P. Chronic heart failure: definition, epidemiology, pathophysiology, clinical manifestations and investigations. In: Julian D, Camm A, Fox K, editors. Diseases of the heart. London: WB Saunders; 1996. p. 467-82.
2. Winaver J, Abassi Z, Green J, Skorecki KL. Control of extracellular fluid volume and the pathophysiology of edema formation. In: Brenner BM, editor. The kidney. Philadelphia: WB Saunders Company; 2000. p. 795-865.
3. Floras JS. Clinical aspects of sympathetic activation and parasympathetic withdrawal in heart failure. J Am Coll Cardiol 1993;22:72A-84A.
4. Katz AM. Cardiomyopathy of overload. A major determinant of prognosis in congestive heart failure. N Engl J Med 1990;322:100-10.
5. Abraham WT, Schrier RW. Renal salt and water handling in congestive heart failure. In: Hosenpud JD, Greenberg BH, editors. Congestive heart failure. Philadelphia: Lippincott Williams & Wilkins; 2000. p. 253-66.
6. Friedman PA, Hebert SC. Physiology of diuretic action. In: Seldin D, Giebisch G, editors. Diuretic agents. San Diego: Academic Press; 1997. p. 75-111.
7. Opie LH, Kaplan NM, Poole-Wilson PA. Diuretics. In: Opie LH, Gersh BJ, editors. Drugs for the heart. Philadelphia: WB Saunders; 2001. p. 84-106.
8. Cooper HA, Dries DL, Davis CE, Shen YL, Domanski MJ. Diuretics and risk of arrhythmic death in patients with left ventricular dysfunction. Circulation 1999;100:1311-5.
9. Francis GS, Benedict C, Johnstone DE, Kirlin PC, Nicklas J, Liang CS, et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990;82:1724-9.
10. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984;311:819-23.
11. Dries DL, Exner DV, Domanski MJ, Greenberg B, Stevenson LW. The prognostic implications of renal insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. J Am Coll Cardiol 2000;35:681-9.
12. Packer M. The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure. J Am Coll Cardiol 1992;20:248-54.
13. Tahara A, Tomura Y, Wada K, Kusayama T, Tsukada J, Ishii N, et al. Effect of YM087, a potent nonpeptide vasopressin antagonist, on vasopressin-induced protein synthesis in neonatal rat cardiomyocyte. Cardiovasc Res 1998;38:198-205.
14. Nielsen S, Chou CL, Marples D, Christensen EI, Kishore BK, Knepper MA. Vasopressin increases water permeability of kidney collecting duct by inducing translocation of aquaporin-CD water channels to plasma membrane. Proc Natl Acad Sci USA 1995;92:1013-7.
15. Palm C, Reimann D, Gross P. The role of V2 vasopressin antagonists in hyponatremia. Cardiovasc Res 2001;51:403-8.
16. Ohnishi A, Orita Y, Okahara R, Fujihara H, Inoue T, Yamamura Y, et al. Potent aquaretic agent. A novel nonpeptide selective vasopressin 2 antagonist (OPC-31260) in men. J Clin Invest 1993;92:2653-9.
17. Lacour C, Galindo G, Canals F, Segondy D, Cazaubon C, Serradeil-Le GC, et al. Aquaretic and hormonal effects of a vasopressin V(2) receptor antagonist after acute and long-term treatment in rats. Eur J Pharmacol 2000;394:131-8.
18. Udelson JE, Smith WB, Hendrix GH, Painchaud CA, Ghazzi M, Thomas I, et al. Acute hemodynamic effects of conivaptan, a dual V1A and V2 vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 2001;104:2417-23.
19. Pelleg A, Porter RS. The pharmacology of adenosine. Pharmacotherapy 1990;10:157-74.
20. Gottlieb S. Renal effects of adenosine A1-receptor antagonists in congestive heart failure. Drugs 2001;61:1387-93.
21. Weaver DR, Reppert SM. Adenosine receptor gene expression in rat kidney. Am J Physiol 1992;263:F991-5.
22. Zou AP, Nithipatikom K, Li PL, Cowley AW Jr. Role of renal medullary adenosine in the control of blood flow and sodium excretion. Am J Physiol 1999;276:R790-8.
23. Schnermann J. Juxtaglomerular cell complex in the regulation of renal salt excretion. Am J Physiol 1998;274:R263-79.
24. Margulies KB, Burnett Jr. JC. Atrial natriuretic factor modulates whole kidney tubuloglomerular feedback. Am J Physiol 1990;259:R97-101.
25. Collis MG, Baxter GS, Keddie JR. The adenosine receptor antagonist, 8-phenyltheophylline, causes diuresis and saliuresis in the rat. J Pharm Pharmacol 1986;38:850-2.
26. Mizumoto H, Karasawa A, Kubo K. Diuretic and renal protective effects of 8-(noradamantan-3-yl)-1,3-dipropylxanthine (KW-3902), a novel adenosine A1-receptor antagonist, via pertussis toxin insensitive mechanism. J Pharmacol Exp Ther 1993;266:200-6.
27. Kost CKJ, Herzer WA, Rominski BR, Mi Z, Jackson EK. Diuretic response to adenosine A(1) receptor blockade in normotensive and spontaneously hypertensive rats: role of pertussis toxin-sensitive G-proteins. J Pharmacol Exp Ther 2000;292:752-60.
28. Wilcox CS, Welch WJ, Schreiner GF, Belardinelli L. Natriuretic and diuretic actions of a highly selective adenosine A1 receptor antagonist. J Am Soc Nephrol 1999;10:714-20.
29. Lonn E, McKelvie R. Drug treatment in heart failure. BMJ 2000;320:1188-92.
30. Delyani JA. Mineralocorticoid receptor antagonists: the evolution of utility and pharmacology. Kidney Int 2000;57:1408-11.
31. Funaya H, Kitakaze M, Node K, Minamino T, Komamura K, Hori M. Plasma adenosine levels increase in patients with chronic heart failure. Circulation 1997;95:1363-5.
32. Silvestre JS, Heymes C, Oubenaissa A, Robert V, Aupetit-Faisant B, Carayon A, et al. Activation of cardiac aldosterone production in rat myocardial infarction: effect of angiotensin II receptor blockade and role in cardiac fibrosis. Circulation 1999;99:2694-701.
33. Silvestre JS, Robert V, Heymes C, Aupetit-Faisant B, Mouas C, Moalic JM, et al. Myocardial production of aldosterone and corticosterone in the rat. Physiological regulation. J Biol Chem 1998;273:4883-91.
34. Weber KT. Aldosterone in congestive heart failure. N Engl J Med 2001;345:1689-97.
35. Lombes M, Alfaidy N, Eugene E, Lessana A, Farman N, Bonvalet JP. Prerequisite for cardiac aldosterone action. Mineralocorticoid receptor and 11 beta-hydroxysteroid dehydrogenase in the human heart. Circulation 1995;92:175-82.
36. Ngarmukos C, Grekin RJ. Nontraditional aspects of aldosterone physiology. Am J Physiol 2001;281:E1122-7.
37. Brilla CG, Pick R, Tan LB, Janicki JS, Weber KT. Remodeling of the rat right and left ventricles in experimental hypertension. Circ Res 1990;67:1355-64.
38. Ewart HS, Klip A. Hormonal regulation of the Na(+)-K(+)-ATPase: mechanisms underlying rapid and sustained changes in pump activity. Am J Physiol 1995;269: C295-311.
39. Horisberger JD, Rossier BC. Aldosterone regulation of gene transcription leading to control of ion transport. Hypertens 1992;19:221-7.
40. Anker SD, Chua TP, Ponikowski P, Harrington D, Swan JW, Kox WJ, et al. Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia. Circulation 1997;96:526-34.
41. Stevens TL, Burnett JCJ, Kinoshita M, Matsuda Y, Redfield MM. A functional role for endogenous atrial natriuretic peptide in a canine model of early left ventricular dysfunction. J Clin Invest 1995;95:1101-8.
42. Brilla CG, Weber KT. Reactive and reparative myocardial fibrosis in arterial hypertension in the rat. Cardiovasc Res 1992;26:671-7.
43. Chapman D, Weber KT, Eghbali M. Regulation of fibrillar collagen types I and III and basement membrane type IV collagen gene expression in pressure overloaded rat myocardium. Circ Res 1990;67:787-94.
44. Fullerton MJ, Funder JW. Aldosterone and cardiac fibrosis: in vitro studies. Cardiovasc Res 1994;28:1863-7.
45. Robert V, Silvestre JS, Charlemagne D, Sabri A, Trouve P, Wassef M, et al. Biological determinants of aldosterone-induced cardiac fibrosis in rats. Hypertens 1995;26:971-8.
46. RALES Investigators. Effectiveness of spironolactone added to an angiotensin-converting enzyme inhibitor and a loop diuretic for severe chronic congestive heart failure [the Randomized Aldactone Evaluation Study (RALES)]. Am J Cardiol 1996;78:902-7.
47. Staessen J, Lijnen P, Fagard R, Verschueren LJ, Amery A. Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol 1981;91:457-65.
48. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-17.
49. Bauersachs J, Fraccarollo D, Ertl G, Gretz N, Wehling M, Christ M. Striking increase of natriuresis by low-dose spironolactone in congestive heart failure only in combination with ACE inhibition: mechanistic evidence to support RALES. Circulation 2000;102:2325-8.
50. Sadee W, Dagcioglu M, Schroder R. Pharmacokinetics of spironolactone, canrenone and canrenoate-K in humans. J Pharmacol Exp Ther 1973;185:686-95.
51. Coats AJ. Exciting new drugs on the horizon - eplerenone, a selective aldosterone receptor antagonist (SARA). Int J Cardiol 2001;80:1-4.
52. de Gasparo M, Joss U, Ramjoue HP, Whitebread SE, Haenni H, Schenkel L, et al. Three new epoxy-spirolactone derivatives: characterization in vivo and in vitro. J Pharmacol Exp Ther 1987;240:650-6.
53. Forssmann W, Meyer M, Forssmann K. The renal urodilatin system: clinical implications. Cardiovasc Res 2001;51:450-62.
54. Inoue T, Nonoguchi H, Tomita K. Physiological effects of vasopressin and atrial natriuretic peptide in the collecting duct. Cardiovasc Res 2001;51:470-80.
55. Kishimoto I, Hamra FK, Garbers DL. Apparent B-type natriuretic peptide selectivity in the kidney due to differential processing. Can J Physiol Pharmacol 2001;79:715-22.
56. Colucci WS, Elkayam U, Horton DP, Abraham WT, Bourge RC, Johnson AD, et al. Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med 2000;343:246-53.
57. Burger AJ, Elkayam U, Neibaur MT, Haught H, Ghali J, Horton DP, et al. Comparison of the occurrence of ventricular arrhythmias in patients with acutely decompensated congestive heart failure receiving dobutamine versus nesiritide therapy. Am J Cardiol 2001;88:35-9.
58. Chen HH, Grantham JA, Schirger JA, Jougasaki M, Redfield MM, Burnett JC Jr. Subcutaneous administration of brain natriuretic peptide in experimental heart failure. J Am Coll Cardiol 2000;36:1706-12.
59. Trippodo NC, Fox M, Monticello TM, Panchal BC, Asaad MM. Vasopeptidase inhibition with omapatrilat improves cardiac geometry and survival in cardiomyopathic hamsters more than does ACE inhibition with captopril. J Cardiovasc Pharmacol 1999;34:782-90.
60. Rouleau JL, Pfeffer MA, Stewart DJ, Isaac D, Sestier F, Kerut EK, et al. Comparison of vasopeptidase inhibitor, omapatrilat, and lisinopril on exercise tolerance and morbidity in patients with heart failure: IMPRESS randomised trial. Lancet 2000;356:615-20.
61. Cataliotti A, Boerrigter G, Chen HH, Jougasaki M, Costello LC, Tsuruda T, et al. Differential actions of vasopeptidase inhibition versus ACE inhibition upon diuretic therapy in experimental CHF. Circulation 2002;105:639-44.
62. Chen HH, Lainchbury JG, Harty GJ, Burnett Jr. JC. Maximizing the natriuretic peptide system in experimental heart failure: subcutaneous BNP and acute vasopeptidase inhibition. Circulation 2002;105:999-1003.